Dabigatran etexilate Liconsa: Uses, Dosage & Side Effects
Direct oral anticoagulant (DOAC) – direct thrombin inhibitor for stroke prevention and blood clot treatment
Dabigatran etexilate Liconsa is a generic direct oral anticoagulant (DOAC) containing dabigatran etexilate, a prodrug that is converted in the body to dabigatran – a potent, reversible, direct thrombin inhibitor. It is prescribed to prevent stroke and systemic embolism in adults with non-valvular atrial fibrillation, to treat and prevent recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent venous thromboembolism after elective hip or knee replacement surgery. Dabigatran etexilate Liconsa is bioequivalent to the originator product Pradaxa.
Quick Facts
Key Takeaways
- Dabigatran etexilate Liconsa is a generic version of Pradaxa, used to prevent stroke in atrial fibrillation and to treat blood clots (DVT and PE).
- It is the only DOAC with a specific monoclonal antibody reversal agent (idarucizumab/Praxbind) for emergency bleeding situations.
- Kidney function must be checked before starting treatment and monitored regularly, as approximately 80% of the drug is eliminated through the kidneys.
- Capsules must be swallowed whole – opening or crushing them significantly increases absorption and bleeding risk.
- Unlike warfarin, dabigatran does not require routine INR blood monitoring and has fewer food and drug interactions.
What Is Dabigatran etexilate Liconsa and What Is It Used For?
Dabigatran etexilate Liconsa contains the active substance dabigatran etexilate, which is a prodrug. After oral administration, it is rapidly converted by esterases in the plasma and liver to its active form, dabigatran. Dabigatran is a potent, competitive, and reversible direct thrombin inhibitor (DTI). Thrombin plays a central role in the coagulation cascade by converting fibrinogen to fibrin, the final step in clot formation. By blocking thrombin, dabigatran effectively prevents the development of blood clots.
This medicine is a generic version of Pradaxa, which was the first DOAC to receive regulatory approval (EMA 2008, FDA 2010). Generic versions like Dabigatran etexilate Liconsa are approved only after demonstrating bioequivalence to the originator product, meaning they deliver the same amount of active drug to the bloodstream at the same rate. This ensures identical clinical efficacy and safety profiles.
Dabigatran etexilate Liconsa is approved for the following indications:
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age 75 years or older, heart failure (NYHA Class II or above), diabetes mellitus, or hypertension.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults, following treatment with a parenteral anticoagulant for at least 5 days.
- Primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip replacement or total knee replacement surgery.
The landmark RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy), published in the New England Journal of Medicine in 2009, was a pivotal study that established dabigatran as an alternative to warfarin. The trial enrolled over 18,000 patients with atrial fibrillation and demonstrated that dabigatran 150 mg twice daily was superior to warfarin in preventing stroke and systemic embolism, while dabigatran 110 mg twice daily was non-inferior to warfarin with significantly lower rates of major bleeding. These results led to widespread global adoption of dabigatran as a first-line anticoagulant for atrial fibrillation.
What Should You Know Before Taking Dabigatran etexilate Liconsa?
Dabigatran etexilate Liconsa is a powerful anticoagulant that requires careful patient selection and ongoing monitoring. While it is generally well tolerated and more convenient than warfarin in many respects, there are important contraindications, precautions, and patient-specific factors that must be considered before initiating therapy. Your prescribing physician will evaluate your individual risk-benefit profile to determine whether dabigatran is appropriate for you.
Contraindications
Dabigatran etexilate Liconsa must not be used in the following situations:
- Known hypersensitivity to dabigatran etexilate, dabigatran, or any of the excipients in the capsule formulation.
- Severe renal impairment (creatinine clearance <30 mL/min in the EU; <15 mL/min in the US per FDA labelling). Dabigatran is approximately 80% renally eliminated, and impaired clearance leads to drug accumulation and excessive bleeding risk.
- Active clinically significant bleeding, including but not limited to gastrointestinal haemorrhage, intracranial haemorrhage, or any site of uncontrolled bleeding.
- Lesions or conditions at significant risk of major bleeding, such as current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, oesophageal varices, arteriovenous malformations, or vascular aneurysms.
- Concomitant treatment with any other anticoagulant (e.g. unfractionated heparin, low molecular weight heparins, warfarin, rivaroxaban, apixaban, edoxaban), except when switching anticoagulant therapy or when heparin is given to maintain a central venous or arterial catheter.
- Hepatic impairment or liver disease expected to have any impact on survival.
- Concomitant treatment with systemic ketoconazole, ciclosporin, itraconazole, dronedarone, and the fixed-dose combination of glecaprevir/pibrentasvir (strong P-glycoprotein inhibitors that significantly increase dabigatran exposure).
- Prosthetic heart valves requiring anticoagulant treatment. The RE-ALIGN trial was terminated early due to excess thromboembolic and bleeding events in patients with mechanical heart valves treated with dabigatran compared to warfarin.
Warnings and Precautions
Special care is required in the following situations, and your doctor may need to adjust your dose, monitor you more closely, or consider an alternative treatment:
- Bleeding risk: As with all anticoagulants, dabigatran should be used with caution in conditions associated with an increased risk of bleeding. Close clinical surveillance is recommended, particularly during the first month of treatment. Signs of bleeding or anaemia should prompt investigation.
- Renal function monitoring: Renal function should be assessed before initiation by calculating creatinine clearance (CrCl) to exclude severe impairment, and should be reassessed at least annually. In patients over 75 years, or in any clinical situation where renal function may decline (hypovolaemia, dehydration, concomitant nephrotoxic medications), monitoring every 3–6 months is recommended.
- Age 75 years and older: Elderly patients have a higher risk of bleeding and often have reduced renal function. A dose of 110 mg twice daily is recommended in most European countries for patients aged 80 and over with atrial fibrillation.
- Low body weight (<50 kg): Limited clinical data are available. Close monitoring is advised.
- Gastrointestinal effects: Dabigatran has been associated with a higher rate of gastrointestinal bleeding compared to warfarin in some studies. Taking the capsules with food or a full glass of water may help reduce dyspepsia. Patients with gastritis, oesophagitis, or gastro-oesophageal reflux may be at higher risk of GI adverse effects.
- Surgical and invasive procedures: Dabigatran should be temporarily discontinued before surgery or invasive procedures, with the timing dependent on renal function and the bleeding risk of the procedure. In emergency surgery, idarucizumab can be used for rapid reversal.
- Spinal/epidural anaesthesia or puncture: There is a risk of epidural or spinal haematoma with neuraxial procedures. Appropriate timing guidelines must be followed.
Premature discontinuation of dabigatran without adequate alternative anticoagulation increases the risk of stroke and other thromboembolic events. If you need to stop taking dabigatran for any reason, speak with your doctor first to ensure a safe transition plan is in place.
Pregnancy and Breastfeeding
Dabigatran etexilate Liconsa is not recommended during pregnancy. Animal studies have shown reproductive toxicity, including reduced foetal body weight and viability at doses associated with maternal toxicity. The potential risk to humans is unknown. Women of childbearing potential should use effective contraception during treatment.
It is not known whether dabigatran is excreted in human breast milk. A decision must be made whether to discontinue breastfeeding or to discontinue dabigatran therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. As a precautionary measure, breastfeeding should be discontinued during treatment.
There are no adequate clinical studies on the effects of dabigatran on human fertility. Animal studies at high doses showed decreased implantation rates and increased pre-implantation loss, but no effects on male fertility were observed.
How Does Dabigatran etexilate Liconsa Interact with Other Drugs?
Unlike warfarin, which is heavily metabolised by cytochrome P450 (CYP) enzymes and has hundreds of known drug and food interactions, dabigatran etexilate is not a substrate of CYP enzymes. Its absorption is primarily regulated by the P-glycoprotein (P-gp) efflux transporter in the gut wall. This means that drugs which inhibit or induce P-gp are the main source of clinically significant interactions with dabigatran. Understanding these interactions is essential for safe prescribing and patient management.
The following table summarises the most clinically important drug interactions. Your doctor or pharmacist should review your complete medication list before starting dabigatran.
Major Interactions
| Interacting Drug | Mechanism | Effect | Clinical Action |
|---|---|---|---|
| Ketoconazole (systemic) | Strong P-gp inhibitor | Increases dabigatran exposure by ~150% | Contraindicated |
| Dronedarone | Strong P-gp inhibitor | Increases dabigatran exposure by ~70–100% | Contraindicated |
| Itraconazole | Strong P-gp inhibitor | Significantly increases dabigatran levels | Contraindicated |
| Ciclosporin | Strong P-gp inhibitor | Significantly increases dabigatran levels | Contraindicated |
| Tacrolimus | P-gp inhibitor | May increase dabigatran exposure | Not recommended; caution required |
| Rifampicin | Strong P-gp inducer | Reduces dabigatran exposure by ~65% | Avoid concomitant use |
| St John's Wort | P-gp inducer | Reduces dabigatran levels | Avoid concomitant use |
| Carbamazepine / Phenytoin | P-gp inducers | Expected reduction in dabigatran levels | Avoid concomitant use |
Moderate and Minor Interactions
| Interacting Drug | Mechanism | Effect | Clinical Action |
|---|---|---|---|
| Amiodarone | Mild P-gp inhibitor | Increases dabigatran exposure by ~12–60% | Consider dose reduction to 150 mg twice daily (AF indication); monitor closely |
| Verapamil | P-gp inhibitor (timing-dependent) | Increases dabigatran exposure by ~12–180% depending on timing | Reduce dose; take dabigatran at least 2 hours before verapamil |
| Quinidine | P-gp inhibitor | Increases dabigatran exposure by ~50% | Dose reduction recommended |
| Aspirin / Clopidogrel | Additive effect on haemostasis | Increased bleeding risk | Use with caution; monitor for bleeding signs |
| NSAIDs (ibuprofen, naproxen) | Additive effect on haemostasis + GI mucosal injury | Increased bleeding risk, especially GI | Avoid chronic use; short-term use with caution |
| SSRIs / SNRIs | Impaired platelet function | Modestly increased bleeding risk | Monitor for bleeding signs |
| Proton pump inhibitors (PPIs) | Increased gastric pH | May reduce dabigatran absorption by ~20–30% | No dose adjustment required; clinical effect considered minimal |
A notable advantage of dabigatran over warfarin is the absence of significant food interactions. There is no need to restrict dietary vitamin K intake, which is a major limitation with warfarin therapy. Patients can eat a normal, varied diet without concern about fluctuations in anticoagulant effect.
What Is the Correct Dosage of Dabigatran etexilate Liconsa?
Dabigatran etexilate Liconsa is taken orally as hard capsules, swallowed whole with a full glass of water, with or without food. It is critical that capsules are not opened, crushed, or chewed, as this increases bioavailability by up to 75%, which significantly raises bleeding risk. The capsules should be removed from the blister packaging immediately before taking them, as they are moisture-sensitive.
Adults – Atrial Fibrillation (Stroke Prevention)
Standard Dose
150 mg twice daily (one 150 mg capsule morning and evening), approximately 12 hours apart. This is the dose shown to be superior to warfarin for stroke prevention in the RE-LY trial.
Reduced Dose
110 mg twice daily is recommended for:
- Patients aged 80 years and over
- Patients taking verapamil concurrently (take dabigatran at least 2 hours before verapamil)
- Patients at higher bleeding risk (e.g. moderate renal impairment CrCl 30–50 mL/min, gastritis, oesophagitis, gastro-oesophageal reflux, or concomitant antiplatelet therapy)
- Patients aged 75–79 years where the physician assesses that the thromboembolic risk is low and the bleeding risk is high
Adults – Treatment of DVT and PE
Treatment Phase
150 mg twice daily following treatment with a parenteral anticoagulant (e.g. heparin) for at least 5 days. The total duration of anticoagulation depends on the clinical context (provoked vs. unprovoked VTE) and is determined by the treating physician, typically at least 3 months for a first episode.
Reduced Dose for DVT/PE
110 mg twice daily should be considered for patients aged 80 years or over, or those taking verapamil concurrently.
Adults – VTE Prevention After Hip or Knee Surgery
Hip Replacement
220 mg once daily (two 110 mg capsules taken as a single dose). Start with 110 mg within 1–4 hours after surgery completion, then 220 mg once daily for a total of 28–35 days.
Knee Replacement
220 mg once daily (two 110 mg capsules taken as a single dose). Start with 110 mg within 1–4 hours after surgery completion, then 220 mg once daily for a total of 10 days.
Reduced Dose for VTE Prevention
150 mg once daily (two 75 mg capsules) for patients with moderate renal impairment (CrCl 30–50 mL/min) or those taking concomitant verapamil. Start with 75 mg within 1–4 hours after surgery.
Children and Adolescents
The safety and efficacy of dabigatran etexilate in children under 18 years of age have not been established for the standard capsule formulation. There is limited data on paediatric use. A specific paediatric formulation (coated granules) has been developed by the originator manufacturer for VTE treatment in children, but this may not apply to all generic versions. Dosing in children, where approved, is weight-based and determined by the treating specialist.
Elderly Patients
Elderly patients are at increased risk of both thromboembolic events and bleeding complications. Renal function declines with age, which directly affects dabigatran clearance. Specific recommendations include:
- Age 75–79 years: The standard dose of 150 mg twice daily can be used for atrial fibrillation, but 110 mg twice daily should be considered if bleeding risk is assessed as high.
- Age 80 years and over: A reduced dose of 110 mg twice daily is recommended for atrial fibrillation (EU labelling). Renal function should be monitored every 3–6 months.
- VTE prevention after surgery: In patients aged 75 and over, or with moderate renal impairment, 150 mg once daily (two 75 mg capsules) is recommended instead of 220 mg.
Missed Dose
If you miss a dose, take it as soon as you remember, provided there are at least 6 hours until the next scheduled dose. If fewer than 6 hours remain, skip the missed dose and take the next dose at the normal time. Never take a double dose to compensate. For once-daily dosing (post-surgical VTE prevention), the missed dose can be taken up to 12 hours before the next scheduled dose.
Overdose
There is no specific antidote for dabigatran overdose in the general sense, but idarucizumab (Praxbind) is available as a specific reversal agent for emergency situations involving life-threatening or uncontrolled bleeding. Idarucizumab is a humanised monoclonal antibody fragment that binds to dabigatran with approximately 350 times greater affinity than thrombin, rapidly and completely neutralising its anticoagulant effect.
In cases of overdose without access to idarucizumab, supportive measures include maintaining adequate diuresis (as dabigatran is renally excreted), administration of activated charcoal if ingestion was recent (within 1–2 hours), and consideration of haemodialysis (which can remove approximately 60% of dabigatran over 2–3 hours due to its low protein binding). Prothrombin complex concentrates (PCCs) or activated PCCs may also be considered.
If you suspect a dabigatran overdose or experience signs of serious bleeding (blood in urine or stool, prolonged nosebleeds, unusual bruising, vomiting blood, severe headache, dizziness, or weakness), seek emergency medical attention immediately.
What Are the Side Effects of Dabigatran etexilate Liconsa?
Like all medicines, dabigatran etexilate Liconsa can cause side effects, although not everybody gets them. The most clinically significant adverse effect is bleeding, which is inherent to its mechanism of action as an anticoagulant. In clinical trials, overall major bleeding rates were comparable to or lower than warfarin, with a particularly notable reduction in intracranial haemorrhage. However, gastrointestinal bleeding was more common with dabigatran 150 mg compared to warfarin.
The following side effect frequency classification is based on data from clinical trials and post-marketing surveillance:
Common
Affects 1 to 10 in every 100 patients
- Gastrointestinal bleeding (including rectal bleeding, haemorrhoidal bleeding, gingival bleeding)
- Dyspepsia (indigestion, stomach discomfort)
- Abdominal pain or discomfort
- Nausea
- Diarrhoea
- Gastritis-like symptoms (inflammation of stomach lining)
- Gastro-oesophageal reflux disease (GORD)
- Decreased haemoglobin levels
- Anaemia
- Epistaxis (nosebleed)
- Urogenital bleeding (blood in urine)
- Skin bleeding (bruising, ecchymosis)
Uncommon
Affects 1 to 10 in every 1,000 patients
- Thrombocytopenia (low platelet count)
- Hypersensitivity reactions (rash, pruritus)
- Intracranial haemorrhage (significantly lower than with warfarin)
- Haematoma or wound bleeding after surgery or trauma
- Haemoptysis (coughing up blood)
- Dysphagia (difficulty swallowing)
- Oesophageal ulcer
- Abnormal liver function tests
- Elevated hepatic transaminases
Rare
Affects 1 to 10 in every 10,000 patients
- Anaphylactic reaction (severe allergic reaction)
- Angioedema (swelling of face, lips, tongue, or throat)
- Urticaria (hives)
- Bronchospasm
- Retroperitoneal haemorrhage
- Musculoskeletal bleeding (haemarthrosis)
- Alopecia (hair loss)
Not Known (Frequency Cannot Be Estimated)
Reported from post-marketing experience
- Oesophageal ulceration (with incorrect capsule administration)
- Neutropenia and agranulocytosis (very rare blood count changes)
Dyspepsia (indigestion) is one of the most commonly reported reasons for dabigatran discontinuation. The capsule contains tartaric acid, which may contribute to GI symptoms. Taking capsules with food, with a full glass of water, or using a proton pump inhibitor (PPI) may help alleviate these symptoms. If persistent GI discomfort occurs, discuss alternative options with your doctor rather than stopping treatment on your own.
If you experience any side effects, including those not listed above, please tell your doctor or pharmacist. You can also report side effects directly via your national adverse drug reaction reporting system (e.g. the Yellow Card Scheme in the UK, MedWatch in the US, or EudraVigilance in the EU).
How Should You Store Dabigatran etexilate Liconsa?
Proper storage of dabigatran etexilate Liconsa capsules is essential to maintain their stability and efficacy. The capsules are particularly sensitive to moisture, which is why they are supplied in specially designed blister packaging or bottles with desiccant closures.
- Store below 30°C (86°F). Do not freeze.
- Keep in the original blister packaging to protect from moisture. Do not transfer capsules to pill organisers or other containers.
- Remove capsules from the blister immediately before use. Do not pre-dispense or remove capsules in advance.
- If supplied in a bottle: keep the bottle tightly closed. Once opened, use within 4 months. The desiccant capsule inside should not be removed.
- Do not use this medicine after the expiry date stated on the carton, blister, or bottle label.
- Keep out of sight and reach of children.
- If capsules appear damaged, discoloured, or have an unusual odour, do not use them.
Do not dispose of medicines via household waste or wastewater. Return unused or expired medicines to your pharmacy for safe disposal. This helps protect the environment.
What Does Dabigatran etexilate Liconsa Contain?
Each hard capsule of Dabigatran etexilate Liconsa 75 mg contains:
Active Substance
- Dabigatran etexilate (as mesilate) – 75 mg per capsule. Dabigatran etexilate is a prodrug with low intrinsic pharmacological activity. Upon oral administration, it is rapidly converted by esterase-catalysed hydrolysis in plasma and the liver to the pharmacologically active compound dabigatran, a direct thrombin inhibitor.
Excipients (Inactive Ingredients)
The inactive ingredients in the capsule formulation typically include:
- Tartaric acid – creates an acidic microenvironment that enhances dissolution and absorption of dabigatran etexilate. This excipient may contribute to the dyspeptic symptoms reported by some patients.
- Acacia (gum arabic) – a binding agent
- Hypromellose – used in the capsule shell
- Dimeticon – an anti-foaming agent
- Talc – a glidant to improve powder flow
- Hydroxypropylcellulose – a binder/coating agent
The capsule shell is composed of hypromellose and may contain colouring agents such as titanium dioxide (E171), iron oxide yellow (E172), indigo carmine (E132), or other standard pharmaceutical colorants depending on the capsule strength. The capsule is printed with pharmaceutical-grade ink.
If you are allergic to any of the listed excipients, or if you have concerns about specific ingredients (such as tartaric acid in relation to GI tolerance), discuss this with your pharmacist or doctor before starting treatment.
Frequently Asked Questions About Dabigatran etexilate Liconsa
Dabigatran etexilate Liconsa is a generic version of Pradaxa. Both contain the same active substance (dabigatran etexilate) at the same dose and in the same pharmaceutical form (hard capsules). Generic medicines are approved only after demonstrating bioequivalence to the originator product through rigorous clinical studies. This means they deliver the same amount of active drug to the bloodstream at the same rate, ensuring identical clinical efficacy and safety. The primary difference is typically the manufacturer and price, with generics generally being more affordable.
Yes, idarucizumab (Praxbind) is a specific reversal agent approved for dabigatran. It is a humanised monoclonal antibody fragment that binds to dabigatran with approximately 350 times greater affinity than thrombin, rapidly and completely neutralising its anticoagulant effect within minutes. The RE-VERSE AD trial demonstrated that idarucizumab reversed the anticoagulant effect of dabigatran in 100% of patients requiring emergency surgery or treatment for uncontrolled bleeding. Dabigatran is the only DOAC with this type of specific antibody reversal agent.
Dabigatran etexilate capsules contain tartaric acid pellets that are specifically formulated to release the drug in a controlled manner. Opening, crushing, or chewing the capsules disrupts this formulation and increases the bioavailability of dabigatran by up to 75%. This significantly higher absorption can lead to dangerously elevated blood levels and a substantially increased risk of serious bleeding. If you have difficulty swallowing capsules, discuss alternative anticoagulant options with your doctor – unlike some other DOACs such as apixaban, dabigatran capsules cannot be crushed or dissolved.
Dabigatran is a direct thrombin (factor IIa) inhibitor, while apixaban, rivaroxaban, and edoxaban are factor Xa inhibitors. The key practical differences include: (1) Dabigatran has a specific monoclonal antibody reversal agent (idarucizumab), while factor Xa inhibitors use andexanet alfa; (2) Dabigatran is more heavily dependent on renal clearance (~80%) compared to apixaban (~27%); (3) Dabigatran has higher rates of GI side effects due to tartaric acid in the formulation; (4) Dabigatran capsules cannot be crushed, while apixaban tablets can be; (5) Dabigatran can be removed by haemodialysis due to low protein binding (~35%), while factor Xa inhibitors cannot. Both drug classes are effective alternatives to warfarin for most indications.
No, unlike warfarin, dabigatran does not interact with dietary vitamin K, so there is no need to restrict your intake of green leafy vegetables or other vitamin K-rich foods. You can eat a normal, varied, and healthy diet. Dabigatran can be taken with or without food. However, taking the capsules with food may help reduce dyspeptic symptoms (indigestion), which is the most common non-bleeding side effect. Drinking a full glass of water with the capsule is also recommended to facilitate swallowing and reduce oesophageal irritation.
Always inform your surgeon, anaesthetist, and dentist that you are taking dabigatran. The timing of when to stop dabigatran before a procedure depends on your kidney function and the bleeding risk of the procedure. For standard-risk procedures: stop at least 24 hours before if CrCl >50 mL/min, or 48 hours if CrCl 30–50 mL/min. For high bleeding-risk procedures: stop at least 48 hours before if CrCl >50 mL/min, or 96 hours if CrCl 30–50 mL/min. Your doctor will provide specific instructions. In emergency surgery, idarucizumab can be administered for rapid reversal.
Moderate alcohol consumption (1–2 drinks occasionally) is generally considered acceptable while taking dabigatran, but excessive or chronic alcohol use should be avoided. Heavy alcohol intake can increase the risk of gastrointestinal bleeding, impair liver function which affects the conversion of the prodrug, and increase the risk of falls and traumatic injuries – which are particularly dangerous while on anticoagulation therapy. Discuss your alcohol habits with your doctor.
References & Evidence Base
All information is based on peer-reviewed medical literature, international clinical guidelines, and regulatory-approved prescribing information.
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation (RE-LY). N Engl J Med. 2009;361(12):1139-1151. doi:10.1056/NEJMoa0905561
- Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal – Full Cohort Analysis (RE-VERSE AD). N Engl J Med. 2017;377(5):431-441. doi:10.1056/NEJMoa1707278
- Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves (RE-ALIGN). N Engl J Med. 2013;369(13):1206-1214. doi:10.1056/NEJMoa1300615
- European Society of Cardiology (ESC). ESC/EACTS Guidelines for the Management of Atrial Fibrillation. Eur Heart J. 2024. doi:10.1093/eurheartj/ehae176
- January CT, Wann LS, Calkins H, et al. AHA/ACC/HRS Focused Update of the 2014 Guideline for Management of Patients with Atrial Fibrillation. J Am Coll Cardiol. 2019;74(1):104-132.
- National Institute for Health and Care Excellence (NICE). Atrial fibrillation: diagnosis and management (NG196). Last updated 2024.
- European Medicines Agency (EMA). Summary of Product Characteristics – Pradaxa. Last updated 2024.
- British National Formulary (BNF). Dabigatran etexilate. Accessed January 2026.
- World Health Organization. WHO Model List of Essential Medicines – 23rd List (2023).
- Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER). N Engl J Med. 2009;361(24):2342-2352. doi:10.1056/NEJMoa0906598
Medical Editorial Team
This article was written and reviewed by our team of specialist physicians following international clinical guidelines and the GRADE evidence framework.
Medical Writers
Licensed physicians with specialisation in clinical pharmacology and haematology. All medical content is evidence-based and follows WHO, ESC, AHA/ACC, and NICE guidelines.
Medical Reviewers
Independent review board of board-certified specialists in internal medicine, cardiology, and clinical pharmacology who verify accuracy, completeness, and clinical relevance of all content.